NCT07298850Active, not recruiting
A Study on the Effect of CGM Alone on Glycemic Metrics in Type 2 Diabetes Patients Not Using Insulin, Without Additional Interventions
Source: ClinicalTrials.gov · Last updated 23 Dec 2025
Brief summary (registry, in English)
This study evaluates the effect of using a real-time continuous glucose monitoring (CGM) system on blood sugar control in people with type 2 diabetes who do not use insulin. Participants will wear a CGM device (CareSens Air) for a total of two weeks. During the first week, the device will be set to "blinded mode," meaning participants cannot see their glucose readings. During the second week, the device will be switched to "unblinded mode," allowing participants to view their glucose levels and trends in real-time. The study aims to determine if simply seeing real-time glucose data can help patients improve their blood sugar control (such as increasing the time their blood sugar is in the target range) without receiving additional structured education on diet or exercise. Researchers will compare the glucose data collected during the blinded week with the data from the unblinded week.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 120 (actual)
- First submitted
- 5 Dec 2025
- Start date
- 30 Sept 2024
- Primary completion date
- 30 Jul 2025
- Lead sponsor
- Kangbuk Samsung Hospital
- Diseases
- Type 2 diabetes
- NCT number
- NCT07298850
What you commit to
- Study type: Interventional
- Participants enrolled: 120
- From 30 Sept 2024 to the primary completion date, 30 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Type 1 diabetes patients
Other
- Insulin users
- Patients who have changed oral hypoglycemic agents within the past 3 months
- Patients scheduled for hospitalization within 2 weeks
- Pregnant women or those planning pregnancy within 1 month
- Those who do not agree to the program
- Those deemed unsuitable for participation in this clinical trial by the investigator
Who the study is looking for
- Patients with Type 2 Diabetes Mellitus (HbA1c ≥ 6.5%, fasting plasma glucose ≥ 126 mg/dL, 2-hour plasma glucose ≥ 200 mg/dL during 75g OGTT, or random plasma glucose ≥ 200 mg/dL with classic symptoms)
- No medication changes in the past 3 months, and receiving treatment with lifestyle modification or oral antidiabetic drugs or GLP-1 receptor agonists
- Ages 19 - 80 years old
- Patients who have voluntarily signed the informed consent form
Age in the registry: 19 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kangbuk Samsung Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.